On January 14, 2026, LENZ Therapeutics launched its first direct-to-consumer marketing initiative for VIZZ™ (aceclidine ophthalmic solution) 1.44%, partnering with award-winning actor and producer Sarah Jessica Parker. The “Make it VIZZable” campaign showcases Parker’s personal experience overcoming age-related blurry near vision using once-daily VIZZ eye drops. Creative elements feature Parker in everyday scenarios—checking text messages, scanning price tags and reading scripts—demonstrating how VIZZ delivers clear near vision for up to ten hours without reading glasses. The campaign will run across digital platforms including Facebook, Instagram, TikTok, YouTube and LinkedIn, driving patients to VIZZ.com to locate prescribing eye-care professionals and request free samples.

Data from the CLARITY Phase 3 trial highlight VIZZ’s robust performance, with 93% of participants achieving near visual acuity of 20/40 or better within 30 minutes of instillation. The effect persisted for up to ten hours, restoring the ability to read phone screens and fine print without corrective lenses. VIZZ’s mechanism—a predominantly pupil-selective miotic action that induces a sub-2 mm pupil and extends depth of focus—differentiates it from traditional therapies by minimizing ciliary muscle stimulation and avoiding a myopic shift. Adverse events were generally mild and transient, with the most common being instillation site irritation (20%), dim vision (16%) and headache (13%).

Presbyopia affects an estimated 128 million Americans and 1.8 billion people globally, with adults over age 50 losing on average 1.5 lines of near vision every six years. LENZ is leveraging its first-to-market FDA approval of an aceclidine-based eye drop to establish VIZZ as a standard alternative to reading glasses. The company has built a nationwide network of prescribing eye-care providers, offers free trial vials, and is actively pursuing international licensing partnerships. Executive leadership anticipates expanding patient access through targeted education efforts and healthcare professional outreach, positioning VIZZ to capture significant share of the presbyopia treatment market.